The most prevalent reasons for exclusion included heparin infusion for less than 24 hours and inadequate protocol compliance. Inadequate protocol compliance was the reason for exclusion in 13 of ...

In conclusion, monitoring intravenous UFH infusions with the anti ... and fewer laboratory tests and heparin dosage changes. Our results provide additional support for the growing sentiment ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

During this period, each center prospectively applied one of three periprocedural protocols: (a) two centers administered aspirin (250 mg IV); (b) one center administered aspirin and heparin (bolus+24 ...